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Amelia J. Eisch, Stephen J. Gold, of this disorder.
and Lisa M. Monteggia
Department of Psychiatry and Center for Diagnosis of Depression
Basic Neuroscience Since the 1960s, depression has been diagnosed as
The University of Texas Southwestern Medical “major depression” based on symptomatic criteria set
Center forth in the Diagnostic and Statistical Manual (DSMIV,
5323 Harry Hines Boulevard 2000) (Table 1). Milder cases are classified as “dysthy-
Dallas, Texas 75390 mia,” although there is no clear distinction between the
two. It is obvious from these criteria (summarized in
Table 1) that the diagnosis of depression, as opposed to
most diseases of other organ systems (diabetes, cancer,Current treatments for depression are inadequate for
chronic obstructive pulmonary disease, to name a few),many individuals, and progress in understanding the
is not based on objective diagnostic tests (serum chem-neurobiology of depression is slow. Several promising
istry, organ imaging, or biopsies), but rather on a highlyhypotheses of depression and antidepressant action
variable set of symptoms. Accordingly, depressionhave been formulated recently. These hypotheses are
should not be viewed as a single disease, but a hetero-based largely on dysregulation of the hypothalamic-
geneous syndrome comprised of numerous diseases ofpituitary-adrenal axis and hippocampus and implicate
distinct causes and pathophysiologies. Attempts havecorticotropin-releasing factor, glucocorticoids, brain-
been made to establish subtypes of depression definedderived neurotrophic factor, and CREB. Recent work
by certain sets of symptoms (Table 2) (see Akiskal, 2000;has looked beyond hippocampus to other brain areas
Blazer, 2000). However, these subtypes are based solelythat are also likely involved. For example, nucleus ac-
on symptomatic differences and there is as yet no evi-cumbens, amygdala, and certain hypothalamic nuclei
dence that they reflect different underlying diseaseare critical in regulating motivation, eating, sleeping,
states.energy level, circadian rhythm, and responses to re-
warding and aversive stimuli, which are all abnormal
Genetic and Environmental Causes of Depressionin depressed patients. A neurobiologic understanding
Epidemiologic studies show that roughly 40%–50% ofof depression also requires identification of the genes
the risk for depression is genetic (Sanders et al., 1999;that make individuals vulnerable or resistant to the
Fava and Kendler, 2000). This makes depression a highlysyndrome. These advances will fundamentally im-
heritable disorder, at least as heritable as several com-prove the treatment and prevention of depression.
mon complex medical conditions (type II diabetes, hy-
pertension, asthma, certain cancers), which are often
Mood disorders are among the most prevalent forms of thought of as genetic. Yet, the search for specific genes
mental illness. Severe forms of depression affect that confer this risk has been frustrating, with no genetic
2%–5% of the U.S. population, and up to 20% of the abnormality being identified to date with certainty. The
population suffer from milder forms of the illness. De- difficulty in finding depression vulnerability genes paral-
pression is almost twice as common in females than lels the difficulty in finding genes for other psychiatric
males. Another roughly 1%–2% are afflicted by bipolar disorders and, in fact, for most common complex dis-
disorder (also known as manic-depressive illness), eases. There are many reasons for this difficulty, which
which affects females and males equally. Mood disor- are reviewed elsewhere (Burmeister, 1999), including
ders are recurrent, life threatening (due to the risk for the fact that depression is a complex phenomenon with
suicide), and a major cause of morbidity worldwide many genes possibly involved. Thus, any single gene
(Blazer, 2000). might produce a relatively small effect and would there-
Depression has been described by mankind for sev- fore be difficult to detect experimentally. It is also possi-
eral millenia. The term melancholia (which means black ble that variants in different genes may contribute to
bile in Greek) was first used by Hippocrates around 400 depression in each family, which further complicates
B.C. (Akiskal, 2000). Most of the major symptoms of the search for depression genes.
depression observed today were recognized in ancient In addition, vulnerability to depression is only partly
times, as were the contributions of innate predisposi- genetic, with nongenetic factors also being important.
tions and external factors in causing the illness. The Nongenetic factors as diverse as stress and emotional
ancients also recognized a large overlap of depression trauma, viral infections (e.g., Borna virus), and even sto-
with anxiety and excessive alcohol consumption, both chastic (or random) processes during brain development
of which are well established today. Indeed, similarities have been implicated in the etiology of depression (Aki-
between ancient descriptions of depression and those skal, 2000; Fava and Kendler, 2000). Depressive syn-
of the modern era are striking, yet it wasn’t until the dromes—indistinguishable from major depression defined
middle part of the 19th century that the brain became by DSMIV and by their response to standard antidepres-
sant treatments—occur in the context of innumerable
medical conditions such as endocrine disturbances1Correspondence: eric.nestler@utsouthwestern.edu
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ment with any of several antidepressant medications orTable 1. Diagnositc Criteria for Major Depression
electroconvulsive seizures (ECS). In addition, several
Depressed mood
forms of psychotherapy (in particular, cognitive and be-Irritability
havioral therapies) can be effective for patients with mildLow self esteem
to moderate cases, and the combination of medicationFeelings of hopelessness, worthlessness, and guilt
Decreased ability to concentrate and think and psychotherapy can exert a synergistic effect.
Decreased or increased appetite The treatment of depression was revolutionized about
Weight loss or weight gain 50 years ago, when two classes of agents were discov-
Insomnia or hypersomnia ered—entirely by serendipity—to be effective antide-
Low energy, fatigue, or increased agitation
pressants: the tricyclic antidepressants and the mono-Decreased interest in pleasurable stimuli (e.g.,
amine oxidase inhibitors. The original tricyclic agentssex, food, social interactions)
(e.g., imipramine) arose from antihistamine research,Recurrent thoughts of death and suicide
whereas the early monoamine oxidase inhibitors (e.g.,
A diagnosis of major depression is made when a certain number of
iproniazid) were derived from work on antitubercularthe above symptoms are reported for longer than a 2 week period
drugs. The discovery that depression can be treatedof time, and when the symptoms disrupt normal social and occupa-
with these medications provided one of the first cluestional functioning (see DSMIV, 2000).
into the types of chemical changes in the brain that
regulate depressive symptoms. Indeed, much depres-
sion research over the last half-century was based on(hyper- or hypocortisolemia, hyper- or hypothyroidism),
the notion that understanding how these treatments
collagen vascular diseases, Parkinson’s disease, trau-
work would reveal new insight into the causes of de-
matic head injury, certain cancers, asthma, diabetes,
pression.
and stroke. The acute mechanisms of action of antidepressant
The role of stress warrants particular comment. De- medications were identified: inhibition of serotonin or
pression is often described as a stress-related disorder, norepinephrine reuptake transporters by the tricyclic
and there is good evidence that episodes of depression antidepressants, and inhibition of monoamine oxidase
often occur in the context of some form of stress. How- (a major catabolic enzyme for monoamine neurotrans-
ever, stress per se is not sufficient to cause depression. mitters) by monoamine oxidase inhibitors (see Frazer,
Most people do not become depressed after serious 1997). These discoveries led to the development of nu-
stressful experiences, whereas many who do become merous second generation medications (e.g., serotonin-
depressed do so after stresses that for most people are selective reuptake inhibitors [SSRIs] and norepineph-
quite mild. Conversely, severe, horrendous stress, such rine-selective reuptake inhibitors) which are widely used
as that experienced during combat, rape, or physical today. The availability of clinically active antidepres-
abuse, does not typically induce depression, but instead sants also made it possible to develop and validate
causes post-traumatic stress disorder (PTSD) that is a wide range of behavioral tests with which to study
distinct from depression based on symptomatology, depression-like phenotypes in animal models. More-
treatment, and longitudinal course of illness. This under- over, these medications and behavioral tests represent
scores the view that depression in most people is important tools with which to study brain function under
caused by interactions between a genetic predisposi- normal conditions and to identify a range of proteins in
tion and some environmental factors, which makes the the brain that might serve as targets for novel antide-
mechanisms of such interactions an important focus of pressant treatments.
investigation. That’s the good news. The bad news is that progress
in developing new and improved antidepressant medi-
Treatment of Depression cations has been limited. The SSRIs, for example, have
In contrast to our limited understanding of depression, a better side effect profile for some patients, and are
there are many effective treatments. The large majority easier for physicians to prescribe, compared with the
older agents. This explains their astonishing financial(80%) of people with depression show some improve-
Table 2. Examples of Proposed Subtypes of Depression
Depression Subtype Main Features
Melancholic depressiona Severe symptoms; prominent neurovegetative abnormalities
Reactive depressionb Moderate symptoms; apparently in response to external factors
Psychotic depression Severe symptoms; associated with psychosis: e.g., believing depression is
a punishment for past errors (a delusion) or hearing voices that
depression is deserved (a hallucination)
Atypical depression Associated with labile mood, hypersomnia, increased appetite, and weight gain
Dysthymia Milder symptoms, but with a more protracted course
These subtypes are based on symptoms only and may not describe biologically distinct entities. The subtypes also cannot generally be
distinguished by different responses to various subclasses of antidepressant medications.
a Melancholic depression is similar to a syndrome classified as “endogenous depression,” based on the speculation that it is caused by innate
factors.
b Reactive depression is similar to a syndrome classified as “exogenous depression,” based on the speculation that it is caused by external
factors.
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success, now a world-wide market of $10 billion a It is likely that many brain regions mediate the diverse
symptoms of depression. This is supported by humanyear in sales. However, these newer medications have
essentially the same mechanism of action as the older brain imaging studies—still in relatively early stages—
which have demonstrated changes in blood flow or re-tricyclic antidepressants and, as a result, the efficacy
of the newer agents and the range of depressed patients lated measures in several brain areas, including regions
of prefrontal and cingulate cortex, hippocampus, stria-they treat are no better than the older medications. To-
day’s treatments remain sub-optimal, with only50% of tum, amygdala, and thalamus, to name a few (Drevets,
2001, Liotti and Mayberg, 2001). Similarly, anatomicall patients demonstrating complete remission, although
many more (up to 80%) show partial responses. studies of brains of depressed patients obtained at au-
topsy have reported abnormalities in many of theseFurthermore, the mechanism of action of antidepres-
sant medications is far more complex than their acute same brain regions (Zhu et al., 1999; Manji et al., 2001;
Drevets, 2001; Rajkowska, 2000). Much work remains,mechanisms might suggest. Inhibition of serotonin or
norepinephrine reuptake or catabolism would be ex- however, since some of the imaging and autopsy studies
have yielded contradictory findings; still, this work haspected to result in enhanced actions of these transmit-
ters. However, all available antidepressants exert their underscored the need to investigate mechanisms of
mood regulation and dysregulation in numerous brainmood-elevating effects only after prolonged administra-
tion (several weeks to months), which means that en- areas.
Knowledge of the function of these brain regions un-hanced serotonergic or noradrenergic neurotransmis-
sion per se is not responsible for the clinical actions of der normal conditions suggests the aspects of depres-
sion to which they may contribute. Neocortex and hippo-these drugs. Rather, some gradually developing adapta-
tions to this enhanced neurotransmission would appear campus may mediate cognitive aspects of depression,
such as memory impairments and feelings of worth-to mediate drug action. Important progress has been
made in the search for such drug-induced plasticity, as lessness, hopelessness, guilt, doom, and suicidality.
The striatum (particularly the ventral striatum or nucleuswill be seen below, but definitive answers are still out of
reach. Moreover, several generations of research have accumbens [NAc]) and amygdala, and related brain ar-
eas, are important in emotional memory, and could asfailed to provide convincing evidence that depression
is caused by abnormalities in the brain’s serotonin or a result mediate the anhedonia (decreased drive and
reward for pleasurable activities), anxiety, and reducednorepinephrine systems. This is consistent with the abil-
ity of “antidepressant” medications to treat a wide range motivation that predominate in many patients. Given the
prominence of so-called neurovegetative symptoms ofof syndromes, far beyond depression, including anxiety
disorders, PTSD, obsessive-compulsive disorder, eating depression, including too much or too little sleep, appe-
tite, and energy, as well as a loss of interest in sex anddisorders, and chronic pain syndromes. It also is consis-
tent with the fact that many medications used in general other pleasurable activities, a role for the hypothalamus
has also been speculated. Of course, these various brainmedicine work far from the molecular and cellular lesion
underlying a disease. regions operate in a series of highly interacting parallel
circuits, which perhaps begins to formulate a neuralThe remainder of this review provides a progress re-
port of what is known about depression and antidepres- circuitry involved in depression (Figure 1).
sant treatments. We first discuss briefly the neural cir-
cuitry of normal mood and of depression. We then Animal Models of Depression
describe the leading animal models that are available A major impediment in depression research is the lack of
today to study mechanisms of depression and antide- validated animal models. Many of the core symptoms of
pressant action. We end by presenting three working depression (e.g., depressed mood, feelings of worth-
hypotheses of the neurobiology of depression, which lessness, suicidality) cannot be easily measured in labora-
highlight both the advances that have been made in tory animals. Also, the lack of known depression vulnera-
understanding this disorder, but also the tremendous bility genes means that genetic causes of depression
amount of work that is still needed to establish the neu- cannot be replicated in animals. As a result, all available
robiologic mechanisms of depression. animal models of depression rely on one of two princi-
ples: actions of known antidepressants or responses to
stress (Table 3) (see Willner, 1995; Hitzemann, 2000;Neural Circuitry of Depression
While many brain regions have been implicated in regu- Porsolt, 2000; Lucki, 2001). Some of these tests (in par-
ticular, the forced swim test) have been very effectivelating emotions, we still have a very rudimentary under-
standing of the neural circuitry underlying normal mood at predicting the antidepressant efficacy of new medica-
tions. They also provide potentially useful models inand the abnormalities in mood that are the hallmark of
depression. This lack of knowledge is underscored by which to study the neurobiologic and genetic mecha-
nisms underlying stress and antidepressant responses.the fact that even if it were possible to biopsy the brains
of patients with depression, there is no consensus in One caveat is that these tests have not yet resulted in
the introduction of medications with truly novel (i.e.,the field as to the site of the pathology, and hence the
best brain region to biopsy. This is in striking contrast non-monoamine-based) mechanisms, although this may
reflect difficulties with clinical trials and the FDA ap-to other neuropsychiatric disorders (e.g., Parkinson’s
disease, Huntington’s disease, Alzheimer’s disease, proval process as much as limitations of the animal
models. Another caveat is that the medications are ac-amyotrophic lateral sclerosis) where pathologic lesions
have been identified in specific regions of the central tive in the animal tests after acute administration, while
their clinical efficacy requires chronic administration. Asnervous system.
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Figure 1. Neural Circuitry of Depression
The figure shows a highly simplified summary
of a series of neural circuits in the brain that
may contribute to depressive symptoms.
While most research in the depression field
has focused on hippocampus (HP) and frontal
cortex (e.g., prefrontal cortex [PFC]), there is
the increasing realization that several subcor-
tical structures implicated in reward, fear, and
motivation are also critically involved. These
include the nucleus accumbens (NAc), amyg-
dala, and hypothalamus. The figure shows
only a subset of the many known intercon-
nections among these various brain regions.
The figure also shows the innervation of sev-
eral of these brain regions by monoaminergic
neurons. The ventral tegmental area (VTA)
provides dopaminergic input to the NAc,
amygdala, PFC, and other limbic structures.
Norepinephrine (from the locus coeruleus or
LC) and serotonin (from the dorsal raphe [DR]
and other raphe nuclei) innervate all of the
regions shown in the figure. In addition, there
are strong connections between the hypo-
thalamus and the VTA-NAc pathway.
a result, it is not known whether the tests are sensitive and antidepressant treatments may work. The three
hypotheses presented below are not comprehensive ofto the true mood-elevating changes that the drugs cause
in the brain or to some other epiphenomena. the field, but provide representative examples of recent
approaches toward understanding depression and anti-Another weakness of available animal models of de-
pression is that they utilize normal mice, while depres- depressant action; they also highlight the work that still
remains.sion probably requires a genetic vulnerability in most
cases. Ultimately, bona fide animal models will only be
developed once the etiology and pathophysiology of Dysregulation of the Hippocampus and
Hypothalamic-Pituitary-Adrenal Axishuman depression are identified. This becomes a catch-
22: we need animal models of depression to better un- A prominent mechanism by which the brain reacts to
acute and chronic stress is activation of the hypothala-derstand the disorders, but such models can only be
developed after we understand the human disorder! De- mic-pituitary-adrenal (HPA) axis (Figure 2). Neurons in
the paraventricular nucleus (PVN) of the hypothalamuspression vulnerability genes will eventually be identified.
During this interim period, one approach would be to secrete corticotropin-releasing factor (CRF), which stim-
ulates the synthesis and release of adrenocorticotropinmake increasing use of animal models of particular as-
pects of depression, for example, cognitive or atten- (ACTH) from the anterior pituitary. ACTH then stimulates
the synthesis and release of glucocorticoids (cortisoltional impairments, or abnormalities in psychomotor ac-
tivity, responses to pleasurable stimuli, and eating and in humans, corticosterone in rodents) from the adrenal
cortex. Glucocorticoids exert profound effects on gen-sleeping behavior (Table 3). These behavioral tests have
not normally been utilized in depression research and eral metabolism and also dramatically affect behavior
via direct actions on numerous brain regions.may offer new insights into the neurobiologic mecha-
nisms involved. The activity of the HPA axis is controlled by several
brain pathways, including the hippocampus (which ex-Despite the pitfalls of available animal models of de-
pression, these models have enabled the field to formu- erts an inhibitory influence on hypothalamic CRF-con-
taining neurons via a polysynaptic circuit) and the amyg-late several hypotheses by which depression may occur
Review
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Table 3. Examples of Animal Models Used in Depression Research
Model Main Features
Forced swim test Antidepressants acutely increase the time an animal struggles in a
chamber of water; lack of struggling thought to represent a state
of despair.
Tail suspension test Antidepressants acutely increase the time an animal struggles when
suspended by its tail; lack of struggling thought of represent a
state of despair.
Learned helplessness Animals exposed to inescapable footshock take a longer time to
escape, or fail to escape entirely, when subsequently exposed
to escapable foot shock; antidepressants acutely decrease
escape latency and failures.
Chronic mild stress Animals exposed repeatedly to several unpredictable stresses (cold,
disruption of light-dark cycle, footshock, restraint, etc.) show
reduced sucrose preference and sexual behavior; however, these
endpoints have been difficult to replicate, particularly in mice.
Social stress Animals exposed to various types of social stress (proximity to domi-
nant males, odors of natural predators) show behavioral abnormal-
ities; however, such abnormalities have been difficult to replicate,
particularly in mice.
Early life stress Animals separated from their mothers at a young age show some
persisting behavioral and HPA axis abnormalities as adults, some
of which can be reversed by antidepressant treatments.
Olfacotry bulbectomy Chemical or surgical lesions of the olfactory bulb cause behavioral
abnormalities, some of which can be reversed by antidepressant
treatments.
Fear conditioning Animals show fear-like responses when exposed to previously neu-
tral cues (e.g., tone) or context (cage) that has been associated
with an aversive stimulus (e.g., shock).
Anxiety-based testsa The degree to which aniamls explores a particular environment (open
space, brightly lit area, elevated area) is increased by anxiolytic
drugs (e.g., benzodiazepines).
Reward-based testsb Animals show highly reproducible responses to drugs of abuse (or
to natural rewards such as food or sex) in classical conditioning
and operant conditioning assays.
Cognition-based testsc The ability of animals to attend, learn, and recall is measured in a
variety of circumstances.
Most of these tests are available in rats and mice; the tail suspension test is used in mice only.
a Examples include open field, dark-light, and elevated plus maze test.
b Examples include conditioned place preference, drug self-administration, conditioned reinforcement, and intra-cranial self-stimulation assays.
c Examples include test of spatial memory (Morris water maze, radial arm maze), working memory (T-maze), and attention (5 choices serial
test).
dala (which exerts a direct excitatory influence) (Figure the hippocampus exerts on the HPA axis, which would
further increase circulating glucocorticoid levels and2). Glucorticoids, by potently regulating hippocampal
and PVN neurons, exert powerful feedback effects on subsequent hippocampal damage.
Such a positive feedback process with pathologicalthe HPA axis. Levels of glucocorticoids that are seen
under normal physiological circumstances seem to en- consequences has been implicated in a subset of de-
pression. Abnormal, excessive activation of the HPAhance hippocampal inhibition of HPA activity. They may
also enhance hippocampal function in general and axis is observed in approximately half of individuals with
depression, and these abnormalities are corrected bythereby promote certain cognitive abilities. However,
sustained elevations of glucocorticoids, seen under antidepressant treatment (Sachar and Baron, 1979; De
Kloet et al., 1988; Arborelius et al., 1999; Holsboer, 2001).conditions of prolonged and severe stress, may damage
hippocampal neurons, particularly CA3 pyramidal neu- Some patients exhibit increased cortisol production, as
measured by increases in urinary free cortisol and de-rons. The precise nature of this damage remains incom-
pletely understood, but may involve a reduction in den- creased ability of the potent synthetic glucocorticoid,
dexamethasone (see Figure 2), to suppress plasma lev-dritic branching and a loss of the highly specialized
dendritic spines where the neurons receive their gluta- els of cortisol, ACTH, and -endorphin (which is derived
from the same peptide precursor as ACTH). There alsomatergic synaptic inputs (Figure 3) (McEwen, 2000; Sa-
polsky, 2000). Stress and the resulting hypercortiso- is direct and indirect evidence for hypersecretion of CRF
in some depressed patients (Arborelius et al., 1999; Hols-lemia also reduce the birth of new granule cell neurons in
the adult hippocampal dentate gyrus (Fuchs and Gould, boer, 2001; Kasckow et al., 2001). ACTH responses to
intravenously administered CRF are blunted, and in-2000). Such hippocampal neurogenesis is proposed to
contribute to memory formation, but this remains con- creased concentrations of CRF have been found in cere-
brospinal fluid. A small number of postmortem studies oftroversial. Regardless of the nature of the damage, it
would be expected to reduce the inhibitory control that depressed individuals have reported increased levels of
Neuron
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rons, as described above. Based on the normal func-
tions subserved by hippocampus, impaired hippocam-
pal function might be expected to contribute to some
of the cognitive abnormalities of depression. Antide-
pressant treatments would work, then, by reversing
these abnormalities, although the molecular and cellular
mechanisms by which prolonged enhancement of
monoamine transmission would produce such actions
are not known.
Stress-induced changes in hippocampus (e.g., reduc-
tion in dendritic arborizations or birth of new neurons)
seen in animal models could be related to the small
reductions in hippocampal volume documented in some
patients with depression (Sheline et al., 1999; Bremner
et al., 2000). However, it is not known whether these
reduced hippocampal volumes are a result of depres-
sion or an antecedent cause. In animal models, several
classes of antidepressants reverse the stress-induced
reductions in dendritic arborizations of hippocampal py-
ramidal neurons (Kuroda and McEwen, 1998; Norrholm
and Ouimet, 2001) as well as increase neurogenesis in
the dentate gyrus (Malberg et al., 2000; Duman et al.,
2001; Manji et al., 2001). However, there is currently no
direct evidence to link dendritic morphology or neuro-
genesis either to the human brain imaging findings or to
the symptomatology of depression in humans or animal
models.
There also are striking parallels between some as-
pects of the stress response, severe depression, and
the effects of centrally administered CRF. These include
increased arousal and vigilance, decreased appetite,
decreased sexual behavior, and increased heart rate
Figure 2. Regulation of the Hypothalamic-Pituitary-Adrenal Axis
and blood pressure (Arborelius et al., 1999; Holsboer,
CRF-containing parvocellular neurons of the paraventricular nucleus
2001). This has led to the proposal that a hyperactiveof the hypothalamus (PVN) integrate information relevant to stress.
HPA axis may contribute to depression not only viaProminent neural inputs include excitatory afferents from the amyg-
hypercortisolemism, but also via enhanced CRF trans-dala and inhibitory (polysynaptic) afferents from the hippocampus,
as shown in the figure. Other important inputs are from ascending mission in the hypothalamus and other brain regions
monoamine pathways (not shown). CRF is released by these neu- that are innervated by these neurons.
rons into the hypophyseal portal system and acts on the cortico- Despite the compelling model outlined above, it is still
trophs of the anterior pituitary to release ACTH. ACTH reaches the unknown whether HPA axis abnormalities are a primary
adrenal cortex via the bloodstream, where it stimulates the release
cause of depression or, instead, secondary to someof glucocorticoids. In addition to its many functions, glucocorticoids
other initiating cause. Nevertheless, a strong case can(including synthetic forms such as dexamethasone) repress CRF
be made for its role in the generation of certain symp-and ACTH synthesis and release. In this manner, glucocorticoids
inhibit their own synthesis. At higher levels, glucocorticoids also toms of depression, and for an impact on the course of
impair, and may even damage, the hippocampus, which could initi- the disease and its somatic sequelae. Such observa-
ate and maintain a hypercortisolemic state related to some cases tions have provided a clear rationale for the use of gluco-
of depression. corticoid or CRF receptor antagonists as novel antide-
pressant treatments. There is growing evidence that
glucocorticoid receptor antagonists, such as mifepri-
CRF in the PVN of the hypothalamus, whereas levels of stone (RU486), may be useful in treating some cases of
CRF receptors are downregulated perhaps as a response depression (Belanoff et al., 2001). Intense attention is
to elevated CRF transmission. Consistent with these being given to antagonists of the CRF1 receptor, the
human data are the observations that rodents separated major CRF receptor in brain, although agents directed
from their mothers early in life show abnormalities in against CRF2 receptors are also of interest (Arborelius
HPA axis function, which resemble those seen in some et al., 1999; Holsboer, 2001). CRF1 receptor antagonists
depressed humans (De Kloet et al., 1988; Francis and exert clear antidepressant-like effects in several stress-
Meaney, 1999; Heim and Nemeroff, 2001). These abnor- based rodent models of depression. These drugs may
malities can persist into adulthood and be corrected by treat depression by limiting hypercortisolism through
antidepressant treatments. actions on the HPA axis (see Figure 2).
How might a hyperactive HPA axis contribute to de- In addition, an action with potentially greater impact
pression? Current hypotheses focus on cortisol and on depression, assuming the drugs prove clinically ef-
CRF. The levels of cortisol seen in some depressed fective, may be inhibition of the CRF system in many
patients, particularly over sustained periods of time, other brain regions, independent of the PVN and the
HPA axis. For example, in amygdala and several relatedmight be high enough to be toxic to hippocampal neu-
Review
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Figure 3. Neurotrophic Mechanisms in Depression
The panel on the left shows a normal hippocampal pyramidal neuron and its innervation by glutamatergic, monoaminergic, and other neurons.
Its regulation by BDNF (derived from hippocampus or other brain areas) is also shown. Severe stress causes several changes in these neurons,
including a reduction in their dendritic arborizations, and a reduction in BDNF expression (which could be one of the factors mediating the
dendritic effects). The reduction in BDNF is mediated partly by excessive glucocorticoids, which could interfere with the normal transcriptional
mechanisms (e.g., CREB) that control BDNF expression. Antidepressants produce the opposite effects: they increase dendritic arborizations
and BDNF expression of these hippocampal neurons. The latter effect appears to be mediated by activation of CREB through the types of
pathways shown in Figure 4. By these actions, antidepressants may reverse and prevent the actions of stress on the hippocampus, and
ameliorate certain symptoms of depression.
brain areas, as will be seen below, CRF is a critical neurotrophic factors in adult brain. Acute and chronic
stress decreases levels of BDNF expression in the den-mediator of fear conditioning and other forms of emo-
tate gyrus and pyramidal cell layer of hippocampus intional memory to both aversive and rewarding stimuli.
rodents (Smith et al., 1995a). This reduction appears to
be mediated partly via stress-induced glucocorticoids
Impairment of Neurotrophic Mechanisms and partly via other mechanisms, such as stress-induced
The pathologic effects of stress on hippocampus, de- increases in serotonergic transmission (Smith et al.,
scribed above, have contributed to another recent hy- 1995a; Vaidya et al., 1997). Conversely, chronic (but not
pothesis, one that proposes a role for neurotrophic fac- acute) administration of virtually all classes of antide-
tors in the etiology of depression and its treatment pressant treatments increases BDNF expression in
(Duman et al., 1997; Altar, 1999). Neurotrophic factors these regions (Nibuya et al., 1995), and can prevent the
were first characterized for regulating neural growth and stress-induced decreases in BDNF levels. There is also
differentiation during development, but are now known evidence that antidepressants increase hippocampal
to be potent regulators of plasticity and survival of adult BDNF levels in humans (Chen et al., 2001b). Antidepres-
neurons and glia. The neurotrophic hypothesis of de- sant induction of BDNF is at least partly mediated via
pression states that a deficiency in neurotrophic support the transcription factor CREB (cAMP response element
may contribute to hippocampal pathology during the binding protein), as described below. Together, these
development of depression, and that reversal of this findings raise the possibility, illustrated in Figure 3, that
deficiency by antidepressant treatments may contribute antidepressant-induced upregulation of BDNF could
to the resolution of depressive symptoms. help repair some stress-induced damage to hippocam-
Work on this hypothesis has focused on brain-derived pal neurons and protect vulnerable neurons from further
damage. Moreover, since BDNF is reported to enhanceneurotrophic factor (BDNF), one of the most prevalent
Neuron
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long-term potentiation and other forms of synaptic plas- buya et al., 1996; Thome et al., 2000). Levels of CREB
are reportedly reduced in temporal cortex (which pre-ticity in hippocampus (Korte et al., 1996; Patterson et
al., 1996; Kang et al., 1997), increased BDNF levels in- sumably included hippocampus) in depressed patients
studied at autopsy (Dowlatshahi et al., 1998). Increasedduced by antidepressants may promote hippocampal
function. The findings could also explain why an antide- CREB activity in the hippocampal dentate gyrus,
achieved by injection of a viral vector encoding CREBpressant response is delayed: it would require sufficient
time for levels of BDNF to gradually rise and exert their directly into this brain region, exerts an antidepressant-
like effect in the forced swim and learned helplessnessneurotrophic effects.
Despite the appeal and heuristic value of this hypothe- tests (Chen et al., 2001a). A palliative effect of CREB
could be related to CREB’s ability to promote long-termsis, direct evidence linking BDNF function in hippocam-
pus to depression is still limited. The most compelling memory in hippocampus (Mayford and Kandel, 1999;
Silva and Murphy, 1999).evidence comes from a recent study, where administra-
tion of BDNF or a related neurotrophin (neurotrophin-3) While these effects of CREB could be mediated via
numerous target genes in addition to BDNF, it doesinto the dentate gyrus or CA3 region of hippocampus
causes antidepressant-like effects in the forced swim illustrate novel strategies by which to influence hippo-
campal function in the context of depression. One posi-and learned helplessness tests (Shirayama et al., 2002).
On the other hand, there is a report that the ability of tive lead along these lines are inhibitors of phosphodies-
terases, the enzymes that degrade cAMP. Severalan antidepressant to reverse the dendritic changes in
CA3 pyramidal neurons caused by stress is not medi- groups have reported that chronic antidepressant treat-
ment upregulates the functioning of the cAMP pathwayated via induction of BDNF (Kuroda and McEwen, 1998).
Mice lacking CREB, which do not show antidepressant in hippocampus and neocortex (see Nestler et al., 1989;
Duman et al., 1997; Thome et al., 2000). (Drug-inducedinduction of BDNF in hippocampus, still show normal
responses to antidepressants in the forced swim test increases in CREB mentioned above would be one com-
ponent of this upregulation.) Consistent with the possi-(Conti et al., 2002).
One limitation in the ability to test the BDNF hypothe- bility that upregulation of the cAMP pathway is relevant
to the therapeutic efficacy of antidepressants is the pre-sis is that mice lacking BDNF die shortly after birth from
peripheral complications. Recently, a conditional knock- liminary clinical observation that rolipram, a type 4 phos-
phodiesterase inhibitor, which would be expected toout of BDNF has been achieved, where the loss of BDNF
occurs late in embryonic development; these mice sur- increase cAMP levels, reduces the symptoms of depres-
sion (see Duman et al., 1997). However, rolipram isvive into adulthood (Rios et al., 2001). The mice show
increased anxiety-like behavior, as well as obesity, but poorly tolerated by humans, due to its many side effects.
The recent cloning of numerous subtypes of type 4no obvious depression-like syndrome has yet been re-
ported. On the other hand, this may relate to current phosphodiesterase, and the demonstration of their re-
gion-specific expression in brain (Takahashi et al., 1999;limitations in animal models of depression as mentioned
earlier. Houslay, 2001), holds promise for the future develop-
ment of more selective agents that are effective antide-This discussion highlights the need for additional experi-
pressants with fewer side effects.mental tools to establish a link between hippocampal
BDNF levels and the formation of depressive symptoms
and their resolution with antidepressant administration. Impairment of Brain Reward Pathways
As is evident from the above discussion, most preclinicalThere also is the need to examine the possible involve-
ment of many other types of neurotrophic factors in studies have focused on the hippocampus as the site
involved in the generation and treatment of depression.stress- and antidepressant-induced changes in hippo-
campal function, and to evaluate the influence of neuro- However, while the hippocampus is undoubtedly in-
volved, it is unlikely that it accounts completely for thesetrophic mechanisms outside the hippocampus. Indeed,
stress decreases BDNF expression in neocortex and phenomena. The hippocampus is best understood for
its role in declarative memory and spatial learning.amygdala, like it does in hippocampus, but increases it
elsewhere (e.g., hypothalamus) (Smith et al., 1995b). In Symptoms affecting learning and memory are certainly
seen in depression, but in many patients such symptomsaddition, infusion of BDNF into the midbrain causes anti-
depressant-like effects (Siuciak et al., 1997), similar to do not represent the overwhelming presentation of the
illness. Indeed, as mentioned earlier, brain imaging andthose seen upon intra-hippocampal administration.
The BDNF hypothesis predicts that agents that pro- autopsy studies have suggested abnormalities in sev-
eral brain areas of depressed individuals well beyond themote BDNF function might be clinically effective antide-
pressants. Currently, no such compounds are available, hippocampus. In recent years, there has been increasing
recognition of the role played by particular subcorticalbut the development of small molecules that regulate
neurotrophic factors or their signaling cascades is a structures (e.g., NAc, hypothalamus, and amygdala) in
the regulation of motivation, sleep, appetite, energymajor focus of drug development efforts. Another ap-
proach would be to intervene earlier in the process, that level, circadian rhythms, and responses to pleasurable
and aversive stimuli, domains which are prominentlyis, in the mechanisms by which antidepressants induce
BDNF expression. There is now considerable evidence affected in most depressed patients (see Table 1). Such
regions have begun to be explored for a role in normalthat CREB is involved. The BDNF gene is induced in
vitro and in vivo by CREB (Tao et al., 1998; Conti et al., mood and depression.
Nucleus Accumbens2002). Moreover, virtually all major classes of antide-
pressants increase levels of CREB expression and func- The NAc is a target of the mesolimbic dopamine system,
which arises in dopaminergic neurons in the ventral teg-tion in several brain regions including hippocampus (Ni-
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mental area (VTA) of the midbrain. These VTA neurons Pliakas et al., 2001; M. Barrot et al., submitted). Based
on these findings, we have recently found that CREB-also innervate several other limbic structures, including
the amygdala and limbic regions of neocortex (Figure mediated transcription is also induced in the NAc in
response to acute and chronic stress (Pliakas et al.,1). The NAc, and its dopaminergic inputs, play critical
roles in reward. Virtually all drugs of abuse increase 2001; M. Barrot et al., submitted). Interestingly, in-
creased CREB function in this brain region decreases andopaminergic transmission in the NAc, which partly me-
diates their rewarding effects (Koob et al., 1998; Wise, animal’s sensitivity to several types of aversive stimuli,
including anxiogenic and nociceptive stimuli, while de-1998). Some drugs produce their rewarding effects in
the NAc also via dopamine-independent mechanisms. creased CREB function increases that sensitivity (M.
Barrot et al., submitted). Thus, it would appear thatFor example, opiates activate dopaminergic transmis-
sion in the NAc via actions in the VTA, but can also CREB in the NAc controls the behavioral responsiveness
of an animal to emotional stimuli in general, such thatdirectly activate  opioid receptors on NAc neurons.
In addition, increasing evidence suggests that similar the increase in CREB seen after stress or drug exposure
may contribute to symptoms of emotional numbing ormechanisms in the VTA and NAc mediate responses to
natural reinforcers under normal conditions as well as anhedonia, which are seen in some forms of depression,
in PTSD, and in drug withdrawal states. The opioid pep-compulsive responses under pathological conditions
(e.g., over-eating, pathological gambling, etc.). Recent tide dynorphin may be one target gene through which
CREB produces this behavioral phenotype (Figure 4)work in nonhuman primates suggests that the firing pat-
terns of VTA dopamine neurons are sensitive readouts (Carlezon et al., 1998; Pliakas et al., 2001).
It is important to note that the proposed action ofof reward expectations: new rewards activate the cells,
whereas the absence of an expected reward inhibits the CREB in the NAc is very different from that proposed
for CREB in hippocampus, where it is implicated in in-cells (Schultz, 2000). A major gap in knowledge is the
means by which altered firing of the dopamine cells, duction of BDNF and antidepressant-like responses in
animal models (see above). This may explain why miceand the consequential altered activity of NAc and other
limbic neurons, mediates “reward.” This will ultimately deficient in CREB show overall normal responses to
antidepressants in certain behavioral tests (Conti et al.,require a circuit level of understanding that is not yet
available. 2002). Thus, a given molecule can exert different (and
even opposing) effects on complex behavior in distinctThe possible involvement of the VTA-NAc pathway in
mood regulation and depression is not well studied. brain regions, based on different targets—and therefore
different effects—of the molecule in distinct types ofThere have been sporadic publications reporting an as-
sociation between the two over the past several de- neurons and on distinct circuits in which the neurons
operate. This highlights the need to view molecularcades (e.g., Willner, 1995; DiChiara et al., 1999; Brown
and Gershon, 1993; Pallis et al., 2001; Yadid et al., 2001). changes that occur in the brain within the context of the
neural circuitry involved.However, research in the depression field has focused
largely on serotonergic and noradrenergic mechanisms Another illustration of this principle is BDNF. BDNF in
hippocampus is implicated in antidepressant action, asin other brain circuits (e.g., hippocampus and neocor-
tex), while research of the VTA-NAc pathway and of described above. In the VTA-NAc pathway, BDNF dra-
matically potentiates drug reward mechanisms (Horgerdopaminergic mechanisms has largely focused on ad-
diction. These distinctions are clearly artificial, and there et al., 1999), while preliminary studies have found that
BDNF in the VTA-NAc produces a depression-like effectis now the need to systematically examine the role of
the VTA-NAc reward pathway in mood regulation. in the forced swim test (E.J.N. and A.J.E., unpublished
observations). These data implicate BDNF within theOne approach would be to use behavioral models of
drug reward in depression research (see Table 3). One mesolimbic dopamine system in the regulation of mood,
motivation, and, possibly, depression, and underscoreof the best examples is a paradigm called intra-cranial
self-stimulation (ICSS) (Hall et al., 1977; Wise, 1996; Ma- the need to examine neural circuits outside the hippo-
campus for a complete understanding of these phe-cey et al., 2000). Animals work (press a lever) to electri-
cally stimulate particular brain areas, including the mes- nomena.
Hypothalamusolimbic dopamine system. Drugs of abuse decrease the
stimulation threshold (intensity of the electrical stimulus) The hypothalamus has long been known to mediate
many neuroendocrine and neurovegetative functions. Itfor which animals will work, whereas aversive conditions
(e.g., drug withdrawal states, severe stress) have the is a highly complex structure; numerous micronuclei
have been characterized by standard histologic tech-opposite effect. It is possible that ICSS provides a novel
measure of an animal’s affective state, which is not eas- niques, yet the neurotransmitters (and particularly the
peptide transmitters) expressed by these various nucleiily inferable from more traditional models of depression.
Another approach would be to examine molecular and are just now being delineated. The hypothalamus has
been studied in the context of depression, althoughcellular changes, which occur in the VTA-NAc pathway
upon exposure to drugs of abuse, in the context of most of this work has focused on the HPA axis (as
outlined above) or other neuroendocrine functions suchdepression models. Recent studies of CREB illustrate
this point. Drugs of abuse have been shown to activate as the hypothalamic-pituitary-thyroid axis. Other hypo-
thalamic functions and nuclei have remained largely un-CREB in the NAc (Berke and Hyman, 2000; Nestler, 2001;
Shaw-Lutchman et al., 2002), and increased CREB func- explored in depression research, despite the fact that
these nuclei and their peptide transmitters are crucialtion in this region has been shown to decrease rewarding
responses to drugs of abuse whereas decreased CREB for appetite, sleep, circadian rhythms, and interest in
sex, which are abnormal in many depressed patients.function has the opposite effect (Carlezon et al., 1998;
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Figure 4. Regulation of NAc Function by
CREB and Dynorphin
The figure shows a VTA dopamine (DA) neu-
ron innervating a class of NAc GABAergic
projection neuron that expresses dynorphin
(Dyn). Dynorphin serves a negative feedback
mechanism in this circuit: dynorphin, re-
leased from terminals of the NAc neurons,
acts on  opioid receptors located on nerve
terminals and cell bodies of the DA neurons
to inhibit their functioning. Regulation of NAc
neurons by glutamate (via projections from
frontal cortex, amygdala, and hippocampus)
and by BDNF (derived from glutamatergic or
dopaminergic neurons) is also shown. Expo-
sure to drugs of abuse or to several forms of
stress upregulates the activity of the dynor-
phin feedback loop via activation of CREB
and induction of dynorphin gene expression.
Such activation of CREB could be mediated
via any of the diverse mechanisms shown in
the figure, all of which lead to the phosphory-
lation of CREB on ser133 and to its activation.
Activation of CREB and induction of dynor-
phin seems to reduce an animal’s sensitivity
to both rewarding and aversive stimuli and
could contribute to certain symptoms of de-
pression. NMDAR, NMDA glutamate recep-
tor; PKA, protein kinase A; CaMKIV, Ca2/cal-
modulin-dependent protein kinase type IV;
RSK-2, ribosomal S6 kinase-type 2; RNA pol,
RNA polymerase II complex.
Hypothalamic mechanisms also could contribute to the enriched in the NAc and dorsal striatum, where activa-
tion of the receptor dramatically antagonizes the re-greatly increased risk of depression among females.
A possible relationship between hypothalamic pep- warding effects of cocaine (R. Hsu et al., submitted).
CART (cocaine- and amphetamine-regulated tran-tides implicated in feeding, and those involved in the
regulation of reward and mood, is particularly striking. script), as its name implies, was first identified in the
NAc based on its drug regulation, but is even moreCRF, part of the stress-responsive HPA axis, is also a
potent anxiogenic and anorexigenic signal (Arborelius enriched in the lateral hypothalamus where it functions
as a potent anorexigenic peptide (Kuhar and Dall Vechia,et al., 1999; Holsboer, 2001; Ahima and Osei, 2001).
Orexin (also known as hypocretin), expressed in the 1999; Ahima and Osei, 2001). Expression of these vari-
ous feeding peptides is controlled by the peripheral hor-lateral hypothalamus, regulates sleep and alertness as
well as eating (Willie et al., 2001) and potently activates mone leptin, and leptin itself has been shown to dramati-
cally diminish ICSS of the lateral hypothalamus (FultonVTA dopamine neurons (Uramura et al., 2001). Melanin
concentrating hormone (MCH), also expressed in the et al., 2000), which provides yet another link between
the hypothalamus and reward and affective state. A sys-lateral hypothalamus, is another potent orexigenic pep-
tide (Ahima and Osei, 2001), and increases sexual be- tematic examination of these hypothalamic factors in
depression models, at the molecular, cellular, and be-havior and reduces anxiety-like behavior as well (Gonza-
lez et al., 1996; Monzon et al., 2001). The MCH receptor havioral levels, is now warranted.
Amygdala(MCH1R) is highly enriched within the NAc (Saito et al.,
2001). Melanocortin (MC or-MSH), expressed in medial The amygdala is best studied for its role in conditioned
fear (Davis, 1998; Cahill et al., 1999; LeDoux, 2000). Ithypothalamus, is an anorexigenic peptide and also in-
creases anxiety-like behavior. Interestingly, one of the mediates the ability of previously nonthreatening stimuli,
when associated with naturally frightening stimuli (e.g,major melanocortin receptors in brain, MC4R, is highly
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exposure to a predator or other severe stresses), to the pervasive symptoms of depression, it is likely that
the pathophysiology of the disorder, and the mecha-elicit a wide range of stress responses. Fear-related
information enters the amygdala via its basal and lateral nisms by which currently available treatments reverse
its symptoms, involve numerous brain regions. Recentnuclei, which also appear to be the site of the plasticity
where these associations are encoded. These nuclei work has begun to incorporate studies of amygdala,
striatal, and hypothalamic circuits with studies of hippo-project to the central nucleus, from which projection
fibers (containing glutamate and in some cases CRF) to campus and neocortex to formulate a more complete
neural circuitry of mood and depression. The neocortex,numerous brain regions produce the diverse physiologi-
cal and behavioral effects characteristic of fear re- in particular, is likely critical for features of depression
that would appear to be peculiarly human (feelings ofsponses. These projection regions include the central
gray (e.g., periaqueductal gray), lateral hypothalamus, worthlessness, hopelessness, guilt, suicidality, etc.), yet
the molecular, cellular, and circuit basis of these com-PVN of hypothalamus, and several monoaminergic nu-
clei. Other brain regions, such as septal nuclei and the plex behaviors remains almost completely obscure.
The ability to image, in the living human brain, thebed nucleus of the stria terminalis, which are functionally
and anatomically related to the amygdala, are also im- various molecules that are implicated in the pathophysi-
ology of depression would represent a dramatic techno-portant for fear and anxiety-like responses. These same
brain regions are implicated in the aversive symptoms logic breakthrough in the field. Current brain imaging
methodologies make it possible to identify gross circuitsseen during withdrawal from drugs of abuse (Koob et
al., 1998). in the brain that are affected in depression as well as a
still small number of neurotransmitter receptors. Im-The amygdala is equally important for conditioned
responses to rewarding stimuli, including drugs of abuse aging BDNF, CREB, various feeding peptides, newly
born dentate gyrus neurons, to name a few, is still farand natural rewards (Everitt et al., 1999). In fact, some
view the amygdala as part of a larger circuit—termed out of reach today, but should be feasible as the field
progresses.the extended amygdala—which also includes the NAc,
bed nucleus of the stria terminalis, and other brain re- Another major need in the field is to understand the
greater risk for depression in women. The neurobiologicgions (de Olmos and Heimer, 1999). It is proposed that
the circuits formed by these structures are critical for basis for this increased risk is unknown, and could con-
ceivably be related to gender differences in hormonalemotional memory, that is, in establishing the emotional
valence of a memory (aversive versus rewarding) as well status or stress response systems, or to sexual dimor-
phism in any of the several brain areas mentioned above.as its strength and persistence.
The molecular basis of the plasticity that occurs in Perhaps functional brain imaging, which would allow
the identification of differential activation of particularthe amygdala and is important for emotional memory is
not as well studied as that in the hippocampus or Nac; brain areas in human patients, will help direct research
into the molecular and cellular mechanisms involved.however, some of the same molecular mediators have
been implicated. The cAMP pathway and CREB in the Ultimately, one key to solving the mystery of depres-
sion lies in genetics. Identifying specific genetic varia-amygdala appear to promote the formation of both aver-
sive and rewarding associations (Hall et al., 2001; Jos- tions that confer risk (or resistance) for depression will
likely be the essential first step in categorizing depres-selyn et al., 2001; Jentsch et al., 2002). Stress decreases
the expression of BDNF in the amygdala (Smith et al., sion based on its underlying biology. Knowing these
genetic abnormalities will then make it possible to estab-1995b), as seen in hippocampus, although the mecha-
nisms involved, and the functional consequences of this lish bona fide animal models of depression, and begin
a long process of delineating, at the molecular, cellular,regulation, remain poorly understood.
The amygdala and its related structures have been and neural circuit levels, how the abnormal genes give
rise to the behavioral abnormalities that define depres-the focus of a great deal of work in the anxiety, PTSD,
and drug addiction fields, but have received relatively sion. Such discoveries will also enable us to understand
how a host of nongenetic factors interact with genes tolittle attention in depression. This despite the fact that
symptoms of anxiety and fear, and abnormal responses cause depressive disorders in vulnerable individuals.
These advances will lead to a second revolution in ourto pleasurable stimuli, are prominent in many depressed
individuals. approach to depression and to the development of de-
finitive treatments and eventually cures and preventiveIt would be interesting to use behavioral tests that
focus on the amygdala (e.g., cue-elicited fear responses, measures.
conditioned aversion or reinforcement assays), as well
as direct manipulations of specific proteins in the amyg- Acknowledgments
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